PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.43 – $1.83
Volume32,046
Market cap$14M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$13.99M
Price / earnings
—
Price / book
0.4×
Price / sales
124.94×
EV / sales
225.97×
EV / EBITDA
-1.07×
Profitability
Earnings per share
-$2.58
Return on assets
-51.29%
Return on equity
-58.85%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.43×
Current ratio
1.19×
Quick ratio
1.19×
Cash ratio
0.93×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PAVM, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$33K
$22K
$52K
$5K
$6K
$8K
$10K
$996K
Cost of revenue
$122K
$97K
$85K
$55K
$41K
$36K
$48K
$1.38M
Gross profit
-$89K
-$75K
-$33K
-$50K
-$35K
-$28K
-$38K
-$385K
Selling, general and administrative
$1.72M
$6.57M
$4.94M
$3.71M
$740K
$4.63M
$4.34M
$9.57M
Research and development
$2.07M
$1.39M
$1.83M
$1.09M
$790K
$787K
$807K
$1.54M
Total operating expenses
$3.78M
$7.96M
$6.77M
$4.79M
$1.53M
$5.42M
$5.15M
$11.19M
Operating income
-$3.87M
-$8.04M
-$6.8M
-$4.84M
-$1.57M
-$5.45M
-$5.19M
-$11.58M
Interest expense
-$2K
-$3K
-$5K
-$8K
-$4K
-$4K
-$7K
-$12K
Income before taxes
-$6.6M
-$1.06M
-$2.76M
-$6.01M
-$12.32M
$18.62M
$1.14M
$60.71M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.6M
-$1.06M
-$2.76M
-$6.01M
-$12.32M
$18.62M
$1.14M
$60.71M
Net income attributable to common shareholders
-$5.48M
-$6.99M
-$1.83M
-$6.33M
-$13.31M
$17.7M
$1.35M
$64.32M
EBITDA
-$3.85M
-$8.02M
-$6.79M
-$4.93M
-$1.54M
-$5.4M
-$5.12M
-$11.5M
Basic earnings per share
-$0.87
-$4.42
-$2.04
-$8.70
-$22.08
$38.26
$3.73
$192.90
Diluted earnings per share
-$0.87
-$4.42
—
-$8.70
-$22.08
$10.10
$0.20
$43.20
Recent news
Company coverage with links to the original publishers.
Lucid Diagnostics Inc. (NASDAQ:LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., announced it will host a business update conference call and webcast on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog will provide a business update and discuss operations and growth strategy, while CFO Dennis McGrath will discuss fourth quarter 2025 financial results.
PAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital Market.
Lucid Diagnostics will host a business update conference call on November 12, 2025, at 8:30 AM ET, where CEO Lishan Aklog will discuss company operations and growth strategy, and CFO Dennis McGrath will review Q3 2025 financial results.
Lucid Diagnostics, a cancer prevention medical diagnostics company, announced plans for a public stock offering to support working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.
PAVmed, a diversified medical technology company, will host a business update conference call and webcast on November 14, 2024, to discuss its third quarter 2024 financial results and provide an overview of its operations and growth strategy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.